Michael Jolley
Keine laufenden Positionen mehr
Profil
Michael Jolley worked for the Diagnostics Division of Abbott Laboratories.
Dr. Jolley was a Co-Founder of Pandex Laboratories, Jolley Consulting, Research, Inc. and Diachemix LLC.
He was a Visiting Fellow for the Section on Carbohydrates at the National Institutes of Health for 2 years and 1 year as a Junior Lecturer in the Chemistry Department of the University of Birmingham.
Dr. Jolley received a BS degree and a PhD in Chemistry from the University of Birmingham.
Ehemalige bekannte Positionen von Michael Jolley
| Unternehmen | Position | Ende |
|---|---|---|
CytoCore, Inc.
 CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Corporate Officer/Principal | - |
Ausbildung von Michael Jolley
| University of Birmingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
CytoCore, Inc.
CytoCore, Inc. Medical SpecialtiesHealth Technology CytoCore, Inc. develops, manufactures and sells an integrated family of products for the detection, diagnosis and treatment of cancer. The company markets its products under the trade name CytoCore Solutions, which is intended to address sample collection, specimen preparation, specimen evaluation, including detection/screening and diagnosis, treatment and patient monitoring within vertical markets related to specific cancers. The company also designs, markets and sells a companion product to detect breast cancer. It intends to focus on the expansion of its products for the treatment of gynecological cancer as well as bladder, lung, and breast cancers amongst others. CytoCore was founded in December 1998 and is headquartered in Chicago, IL. | Health Technology |
